tradingkey.logo
tradingkey.logo
Search

Grail Inc

GRAL
Add to Watchlist
68.560USD
-2.580-3.63%
Close 07-31 16:00ETQuotes delayed by 15 min
2.94BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-3.63%

5 Days

+1.06%

1 Month

+0.66%

6 Months

-29.91%

Year to Date

-19.90%

1 Year

+109.09%

Key Figures
71.500Open
71.570High
560.43KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.36%Turnover Ratio
71.140Prev. Close
67.160Low
27.13MTurnover
LossP/E Static
1.13P/B
0.00%Div Yield TTM
-13.99%ROA
118.84052wk High
0.98Volume Ratio
-2.03BNet Profit
41.13MShares
-10.3076EPS TTM
--Beta
-16.09%ROE
29.95052wk Low
6.20%Amplitude
-35.08%Gross Margin
2.94BMarket Cap
0.68Reward/Risk
4.69%Risk Rate

TradingKey Stock Score of Grail Inc

Currency: USD Updated: 2026-07-31

Key Insights

Grail Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 62 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 68.39.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Grail Inc's Score

Industry at a Glance

Industry Ranking
62 / 385
Overall Ranking
137 / 4281
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Grail Inc Highlights

StrengthsRisks
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.07% year-on-year.
Undervalued
The company’s latest PE is -6.65, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 33.74M shares, increasing 4.97% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 22.82K shares of this stock.

Analyst Rating

Based on 9 analysts
Buy
Current Rating
68.391
Target Price
+7.80%
Upside Space

Grail Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 9 analysts
Buy
Current Rating
68.391
Target Price
+7.80%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Grail Inc
GRAL
9
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99

Indicators

Indicators
Sell(1)
Neutral(4)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
-1.366
Neutral
RSI(14)
50.550
Neutral
STOCH(KDJ)(9,3,3)
51.035
Buy
ATR(14)
4.108
High Vlolatility
CCI(14)
-22.432
Neutral
Williams %R
50.497
Neutral
TRIX(12,20)
0.102
Sell
StochRSI(14)
69.326
Buy
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
66.866
Buy
MA10
68.481
Buy
MA20
70.217
Sell
MA50
66.797
Buy
MA100
59.609
Buy
MA200
74.246
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Grail Inc Info

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Ticker SymbolGRAL
CompanyGrail Inc
CEORagusa (Robert)
Websitehttps://grail.com/

Shareholders

Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.80%
Farallon Capital Management, L.L.C.
5.46%
Baker Bros. Advisors LP
4.86%
PRIMECAP Management Company
4.30%
State Street Investment Management (US)
4.26%
Other
75.32%

FAQs

What is the current price of Grail Inc (GRAL)?

The current price of Grail Inc (GRAL) is 68.56.

What is the symbol of Grail Inc?

The ticker symbol of Grail Inc is GRAL.

What is the 52-week high of Grail Inc?

The 52-week high of Grail Inc is 118.84.

What is the 52-week low of Grail Inc?

The 52-week low of Grail Inc is 29.95.

What is the market capitalization of Grail Inc?

The market capitalization of Grail Inc is 2.82B.

Is Grail Inc (GRAL) currently rated as Buy, Hold, or Sell?

According to analysts, Grail Inc (GRAL) has an overall rating of Buy, with a price target of 68.39.

What is the Earnings Per Share (EPS TTM) of Grail Inc (GRAL)?

The Earnings Per Share (EPS TTM) of Grail Inc (GRAL) is -11.11.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.